RxDoctor Payments Data

Luis Montalvo, MD

Ophthalmology · Arecibo, PRNPI 1376639575

Payments from drug & device makers

$747in general payments, 2019–2025

Across 26 payments — averaging $28.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$303
  • Novartis$119
  • Alcon Puerto Rico Inc$111
  • Alcon$97
  • Bausch & Lomb Americas Inc.$61
  • Johnson & Johnson$20
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$73098%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)11$303
Novartis5$119
Alcon Puerto Rico Inc3$111
Alcon2$97
Bausch & Lomb Americas Inc.2$61
Johnson & Johnson1$20
Zimmer Biomet1$19
Bausch & Lomb, A Division Of Bausch Health US, LLC1$17

How this compares

$747 in reported general payments places this provider in the 50th percentile of 214 ophthalmology providers in Puerto Rico.

See all ophthalmology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,283
Medicare patients
80
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost399$103,712
Fluorometholone803$53,971
CombiganBrimonidine Tartrate/Timolol232$49,289
Prednisolone Acetate1,016$39,721
Latanoprost3,151$38,544
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol217$33,745
RestasisCyclosporine79$31,247
Brimonidine Tartrate1,395$27,314
Alphagan PBrimonidine Tartrate134$26,507
Timolol Maleate1,353$17,584
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat258$8,157
SimbrinzaBrinzolamide/Brimonidine Tart37$7,549
Tobramycin-DexamethasoneTobramycin/Dexamethasone169$7,176
Cyclosporine48$6,758
Dorzolamide Hcl204$6,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$303$210,755844 claims
AlconSimbrinza$97$7,54937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 214 ophthalmology providers in Puerto Rico.

Other ophthalmology in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →